On the public citation graph

‘Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases

0 signed · 99 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.breast.2007.07.041openalex-snapshot
Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases
inferredcites →https://doi.org/10.1038/modpathol.3800774openalex-snapshot
Standardization of HER2 testing: results of an international proficiency-testing ring study
inferredcites →https://doi.org/10.1046/j.1365-2885.2001.0363b.xopenalex-snapshot
In Reply
inferredcites →https://doi.org/10.1056/nejmoa052306openalex-snapshot
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa054504openalex-snapshot
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
inferredcites →https://doi.org/10.1097/01.lab.0000032371.16521.40openalex-snapshot
Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer
inferredcites →https://doi.org/10.1097/pdm.0b013e318064c72aopenalex-snapshot
Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast
inferredcites →https://doi.org/10.1111/j.1524-4741.2007.00396.xopenalex-snapshot
Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare Event
inferredcites →https://doi.org/10.1126/science.3798106openalex-snapshot
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
inferredcites →https://doi.org/10.1136/jcp.2007.048991openalex-snapshot
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals
inferredcites →https://doi.org/10.1159/000318043openalex-snapshot
A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1177/1066896906293055openalex-snapshot
Intratumoral Heterogeneity of HER-2/neu in Invasive Mammary Carcinomas Using Fluorescence In-Situ Hybridization and Tissue Microarray
inferredcites →https://doi.org/10.1186/1471-2407-9-165openalex-snapshot
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis
inferredcites →https://doi.org/10.1200/jco.1999.17.7.1974openalex-snapshot
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.1999.17.7.1983openalex-snapshot
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
inferredcites →https://doi.org/10.1200/jco.2000.18.21.3651openalex-snapshot
Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
inferredcites →https://doi.org/10.1200/jco.2006.09.2775openalex-snapshot
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.520openalex-snapshot
Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial
inferredcites →https://doi.org/10.1309/ajcp0en6aqmwetzzopenalex-snapshot
HeterogeneousHER2Gene Amplification
inferredcites →https://doi.org/10.3892/ijo.22.2.237openalex-snapshot
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)
inferredcites →https://doi.org/10.5858/133.4.611openalex-snapshot
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
inferredcites →https://doi.org/10.5858/134.2.162.aopenalex-snapshot
Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer.
inferredcites →https://doi.org/10.5858/134.2.162.bopenalex-snapshot
Is It Too Soon To Start Reporting HER2 Genetic Heterogeneity?
inferredcites →https://doi.org/10.5858/134.2.163.aopenalex-snapshot
In Reply
inferredcites →https://doi.org/10.5858/134.2.163.bopenalex-snapshot
Resident preparation for practice.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4851024openalex-extracted
Comprehensive Review on Computational In-Situ Hybridization (Ish) Digital Pathology Using Image Analysis Techniques: Principles and Applications
inferred← citeshttps://doi.org/10.1002/gcc.22113openalex-snapshot
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
inferred← citeshttps://doi.org/10.1002/path.5914openalex-snapshot
Leveraging single‐cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers
inferred← citeshttps://doi.org/10.1007/978-1-4939-1578-1_14openalex-snapshot
Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu
inferred← citeshttps://doi.org/10.1007/978-1-62703-706-8_10openalex-snapshot
FISH Methods in Cytogenetic Studies
inferred← citeshttps://doi.org/10.1007/978-3-030-16518-5_2openalex-snapshot
Invasive Ductal Carcinoma (NOS) of the Breast
inferred← citeshttps://doi.org/10.1007/978-3-030-83328-2_15openalex-snapshot
Predictive Biomarkers in Breast Cancer: ER, PR, and HER-2/NEU
inferred← citeshttps://doi.org/10.1007/978-981-13-5877-7_15openalex-snapshot
Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast
inferred← citeshttps://doi.org/10.1007/s00428-016-1903-3openalex-snapshot
Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment
inferred← citeshttps://doi.org/10.1007/s00428-017-2189-9openalex-snapshot
Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization
inferred← citeshttps://doi.org/10.1007/s10549-017-4453-8openalex-snapshot
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
inferred← citeshttps://doi.org/10.1016/j.ajpath.2023.11.015openalex-snapshot
Vision Transformers for Breast Cancer Human Epidermal Growth Factor Receptor 2 Expression Staging without Immunohistochemical Staining
inferred← citeshttps://doi.org/10.1016/j.anndiagpath.2015.08.001openalex-snapshot
Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks
inferred← citeshttps://doi.org/10.1016/j.clbc.2014.11.009openalex-snapshot
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy
inferred← citeshttps://doi.org/10.1016/j.clbc.2019.08.001openalex-snapshot
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2020.102064openalex-snapshot
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
inferred← citeshttps://doi.org/10.1016/j.ctrv.2023.102618openalex-snapshot
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
inferred← citeshttps://doi.org/10.1016/j.ejca.2012.10.018openalex-snapshot
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2013.12.010openalex-snapshot
Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
inferred← citeshttps://doi.org/10.1016/j.humpath.2022.05.011openalex-snapshot
Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity
inferred← citeshttps://doi.org/10.1016/j.jpi.2022.100116openalex-snapshot
Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer
inferred← citeshttps://doi.org/10.1016/j.labinv.2025.104240openalex-snapshot
Analysis of Human Epidermal Growth Factor Receptor 2 (HER2) Heterogeneity at the Protein and Gene Levels in Endometrial Cancer: Refining HER2 Reporting and HER2-Directed Therapies
inferred← citeshttps://doi.org/10.1016/j.modpat.2025.100785openalex-snapshot
Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response
inferred← citeshttps://doi.org/10.1016/j.modpat.2026.101074openalex-snapshot
HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions
inferred← citeshttps://doi.org/10.1016/j.molmed.2012.10.003openalex-snapshot
Toponome imaging system: multiplex biomarkers in oncology
inferred← citeshttps://doi.org/10.1016/j.mpdhp.2019.10.014openalex-snapshot
The assessment of HER2 status and its clinical implication in breast cancer
inferred← citeshttps://doi.org/10.1016/j.prp.2016.09.014openalex-snapshot
Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.02.016openalex-snapshot
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
inferred← citeshttps://doi.org/10.1038/modpathol.2012.213openalex-snapshot
Letter to the editor regarding ‘Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'
inferred← citeshttps://doi.org/10.1038/modpathol.2013.103openalex-snapshot
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
inferred← citeshttps://doi.org/10.1038/modpathol.2016.175openalex-snapshot
‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study
inferred← citeshttps://doi.org/10.1038/s41374-018-0172-yopenalex-snapshot
High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer
inferred← citeshttps://doi.org/10.1038/s41379-021-00813-xopenalex-snapshot
HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity
inferred← citeshttps://doi.org/10.1038/srep41921openalex-snapshot
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
inferred← citeshttps://doi.org/10.1053/j.semdp.2022.06.015openalex-snapshot
Update on prognostic and predictive biomarkers of breast cancer
inferred← citeshttps://doi.org/10.1093/ajcp/aqw117openalex-snapshot
Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer
inferred← citeshttps://doi.org/10.1093/ajcp/aqw211openalex-snapshot
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
inferred← citeshttps://doi.org/10.1093/ajcp/aqz010openalex-snapshot
Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity
inferred← citeshttps://doi.org/10.1097/md.0000000000013666openalex-snapshot
Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer
inferred← citeshttps://doi.org/10.1097/pai.0000000000000136openalex-snapshot
HER2 Genetic Heterogeneity in Gastric Cancer
inferred← citeshttps://doi.org/10.1111/his.13733openalex-snapshot
Equivocal (HER2 IHC 2+) breast carcinomas: gene–protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits
inferred← citeshttps://doi.org/10.1111/his.14001openalex-snapshot
Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation‐dependent probe amplification: a descriptive study
inferred← citeshttps://doi.org/10.1111/pin.12407openalex-snapshot
The assessment of HER2 status in breast cancer: the past, the present, and the future
inferred← citeshttps://doi.org/10.1111/tbj.12858openalex-snapshot
Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period
inferred← citeshttps://doi.org/10.1136/jclinpath-2012-201403openalex-snapshot
Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis
inferred← citeshttps://doi.org/10.1136/jclinpath-2016-203644openalex-snapshot
Validity of whole slide images for scoring HER2 chromogenic in situ hybridisation in breast cancer
inferred← citeshttps://doi.org/10.1155/2017/2321916openalex-snapshot
Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-15-0887openalex-snapshot
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
inferred← citeshttps://doi.org/10.1177/107327481502200213openalex-snapshot
Advances in the Molecular Analysis of Breast Cancer: Pathway toward Personalized Medicine
inferred← citeshttps://doi.org/10.1186/s13058-024-01779-9openalex-snapshot
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1186/s42047-026-00238-3openalex-snapshot
HER2-low and ultra-low breast cancer: expanding the therapeutic spectrum in precision oncology
inferred← citeshttps://doi.org/10.1200/jco.2013.50.9984openalex-snapshot
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
inferred← citeshttps://doi.org/10.1309/ajcpiv9iq1mrqmooopenalex-snapshot
Molecular Pathology of Breast Cancer
inferred← citeshttps://doi.org/10.1309/ajcpzsv2w1cpgrjwopenalex-snapshot
HER2 Testing of Multifocal Invasive Breast Carcinoma
inferred← citeshttps://doi.org/10.1586/14737159.2013.835568openalex-snapshot
Meeting the challenges of PET-based molecular imaging in cancer
inferred← citeshttps://doi.org/10.1586/14737159.2015.992416openalex-snapshot
HER2 assessment by silverin situhybridization: where are we now?
inferred← citeshttps://doi.org/10.17116/patol201577543-51openalex-snapshot
Use of the new 2013 ASCO/CAP guidelines to study HERS status by fluorescence in situ hybridization in patients with breast cancer
inferred← citeshttps://doi.org/10.17116/patol201577621-28openalex-snapshot
Immunohistochemical changes in the lungs from fetuses and newborn infants at 20—40 weeks’ gestation with false left-sided congenital diaphragmatic hernia
inferred← citeshttps://doi.org/10.18632/oncotarget.16067openalex-snapshot
Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.24265openalex-snapshot
Prognostic implications of HER2 heterogeneity in gastric cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.5368openalex-snapshot
Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
inferred← citeshttps://doi.org/10.2217/fon.14.19openalex-snapshot
HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?
inferred← citeshttps://doi.org/10.3389/fonc.2022.955943openalex-snapshot
Lentiviral vector–based xenograft tumors as candidate reference materials for detection of HER2-low breast cancer
inferred← citeshttps://doi.org/10.3390/cancers15102664openalex-snapshot
HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
inferred← citeshttps://doi.org/10.3390/cancers16051062openalex-snapshot
High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers17132126openalex-snapshot
High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.3390/diagnostics14182089openalex-snapshot
Review of In Situ Hybridization (ISH) Stain Images Using Computational Techniques
inferred← citeshttps://doi.org/10.3390/ijms24098206openalex-snapshot
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
inferred← citeshttps://doi.org/10.3791/56686openalex-snapshot
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
inferred← citeshttps://doi.org/10.5858/arpa.2013-0953-saopenalex-snapshot
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
inferred← citeshttps://doi.org/10.5858/arpa.2020-0207-raopenalex-snapshot
HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand
inferred← citeshttps://doi.org/10.5858/arpa.2022-0335-raopenalex-snapshot
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
inferred← citeshttps://doi.org/10.5858/arpa.2024-0305-oaopenalex-snapshot
Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision
inferred← citeshttps://doi.org/10.6084/m9.figshare.26677907openalex-snapshot
Additional file 1 of Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.